BOSTON (TheStreet) -- Earlier today, I posted 13 biotech stock predictions for 2013. Now, it's your turn to make best guesses on the winner and losers during the coming year.
I threw out a request on Twitter yesterday for 2013 biotech stock predictions. The response was amazing and overwhelming. Thanks to everyone who contributed. I'll be sure to check back throughout the year to check the accuracy of TheStreet's biotech readers.
If you agree, disagree or feel like something is missing from this list, please share your thoughts and comments below.
TheStreet readers' 2013 biotech stock predictions:
AMRN - still independent, launch sales - they will spend much more on mkting, admin, sales than actual gains from product sales. No NCE/— Sport234a2b (@Sport234a) January 1, 2013
my wildest 2013 prediction : $TRGT will be bought in the low 10s— max (@LTbioinvestor) January 1, 2013
@adamfeuerstein $IMUC ict-107 offers statistically significant OS— Shitmylabmatesays (@Shtmylabmatesez) January 1, 2013
@adamfeuerstein my wildest prediction: $CYTK breaks thru $1. benefit in ALS+partner.meets 1ary endpnt in HF— Juan P. Serrate, DVM (@JPZaragoza1) January 1, 2013
@adamfeuerstein Amrn BO price $23 by April— mimosttr (@trstmomi) January 2, 2013
SRPT - expect FDAyes 4 a NDA filing based on current data, a very tough panel review potential late 13, very volatile stk in 13.— Sport234a2b (@Sport234a) January 1, 2013
Prosensa/GSK - sadly, my leaning is a miss for their DMD P3, my problem is w/enrollment criteria, and countries involved.— Sport234a2b (@Sport234a) January 1, 2013
@adamfeuerstein $GSK will buy the rest of $FOLD 5-6 range. $INCY will be bid for by several BP's making it the star of the year.— JNV (@JNVcapital) January 1, 2013
@adamfeuerstein Biotech cos add buy-back provisions in outlicens deals. One co will raise money to exercise; partner will buy the co instead— David Sable (@dbsable) January 1, 2013
@adamfeuerstein $SGMO and other HIV-elimination (cure) technologies emerge as a threat to $GILD $JNJ $MRK $GSK and others— Martin Shkreli (@MartinShkreli) January 1, 2013
@adamfeuerstein inflammation platforms become the biotech theme for 2013— Norcaljosh (@norcaljosh) January 1, 2013
.@adamfeuerstein Mdvn pre-chemo data trumps zytiga by 2 months. Combo trials gives PCA patients an extra 8 months (2014 data?). Dndn dies.— daviesbj (@daviesbj) January 1, 2013
@adamfeuerstein APPA is the best performer out of all of the he "A" stocks(AMRN, ARNA, ALXA have TERRIBLE launches and stock prices suffer)— Chet Stedman (@ChetStedman5) January 1, 2013
@adamfeuerstein Mnkd will be the biotech of the year.— Al Marino (@optiontrader78) January 1, 2013
@adamfeuerstein My prediciton?No matter what biotech I am in, I'm gonna get f----d one way or the other.— TraderNeal (@traderneal) January 1, 2013
@adamfeuerstein I predict the anti-PD1s will be big successes in multiple solid tumor types. Lung and melanoma in particular. $BMY and $MRK— Chris Ahlstrand (@ahlstrac) January 1, 2013
@adamfeuerstein Initiation of multiple HCV trials of 2 or 3 drug nuke/2nd gen NS5As/PI combos with treatment duration 6 weeks or less— John Alan Tucker (@JohnTuckerPhD) January 1, 2013
@adamfeuerstein I predict you are accused of being a hedge fund shill at least 500x in 2013— Stock Jock (@hedgeorbehedged) January 1, 2013
@adamfeuerstein Some speculative predictions: ACHN does a deal w/ABT or JNJ for 3102. 1625 remains unpartnered.— John Alan Tucker (@JohnTuckerPhD) January 1, 2013More biotech stock prediction Tweets on the next page.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
